AEZS-127
ErPC (oncology)
Therapeutic area
Oncology
Target indication
Multiple cancers
Development stage
Preclinical development
Description
AEZS-127 (Erucylphosphocholine (ErPC)) is an analog of perifosine which is suitable for intravenous administration. Like perifosine, AEZS-127 belongs to a new class of compounds based on alkylphosphocholines that Æterna Zentaris has developed in our Drug Discovery group. AEZS-127 possesses distinctive reduced hemolytic activity thus allowing for intravenous injection.
Mode of action
In tumor cells, AEZS-127 demonstrated interactions with vital signal transduction mechanisms and showed induction of programmed cell death (apoptosis). AEZS-127 inhibits Akt- and Raf-Mek-Erk- signalling and interferes primarily with membranes of proliferating cells.
Partnership status
Æterna Zentaris owns the worldwide rights.
|
